Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

医学 安慰剂 临床终点 内科学 药效学 骨关节炎 药代动力学 不利影响 随机对照试验 胃肠病学 外科 麻醉 病理 替代医学
作者
M. Kloppenburg,CHARLES G. PETERFY,Ida Kristin Haugen,Féline P B Kroon,Su Chen,Li Wang,Wei Yong Liu,Gwen Levy,Roy Fleischmann,Françis Berenbaum,Désirée M F M van der Heijde,Prashant N. Bansal,Ruth Wittoek,Sheng Feng,Yuni Fang,Mary J. Saltarelli,Jeroen K Medema,Marc C. Levesque
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:78 (3): 413-420 被引量:181
标识
DOI:10.1136/annrheumdis-2018-213336
摘要

OBJECTIVE: To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). METHODS: Patients with ≥1 erosive and ≥3 tender and/or swollen hand joints were randomised to placebo or lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks. The primary endpoint was change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks. At baseline and week 26, subjects had bilateral hand radiographs and MRI of the hand with the greatest number of baseline tender and/or swollen joints. Continuous endpoints were assessed using analysis of covariance models, with treatment and country as main factors and baseline measurements as covariates. RESULTS: Of 132 randomised subjects, 1 received no study drug and 110 completed the study (placebo, 61/67 (91%); lutikizumab, 49/64 (77%)). AUSCAN pain was not different among subjects treated with lutikizumab versus placebo at week 16 (least squares mean difference, 1.5 (95% CI -1.9 to 5.0)). Other clinical and imaging endpoints were not different between lutikizumab and placebo. Lutikizumab significantly decreased serum high-sensitivity C reactive protein levels, IL-1α and IL-1β levels, and blood neutrophils. Lutikizumab pharmacokinetics were consistent with phase I studies and not affected by antidrug antibodies. Injection site reactions and neutropaenia were more common in the lutikizumab group; discontinuations because of adverse events occurred more frequently with lutikizumab (4/64) versus placebo (1/67). CONCLUSION: Despite adequate blockade of IL-1, lutikizumab did not improve pain or imaging outcomes in erosive HOA compared with placebo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wang完成签到,获得积分10
刚刚
Yaqi发布了新的文献求助10
刚刚
Renea完成签到,获得积分10
刚刚
1秒前
1秒前
小郭发布了新的文献求助10
1秒前
1秒前
1秒前
Orange的应助被JH_采纳,获得10
2秒前
2秒前
2秒前
李健的小迷弟的应助被adai007采纳,获得10
2秒前
nepdiana的应助被勤劳的薯片采纳,获得30
2秒前
333完成签到,获得积分20
3秒前
Taro完成签到,获得积分10
3秒前
碧蓝山水完成签到,获得积分10
3秒前
nanana完成签到,获得积分10
3秒前
3秒前
4秒前
LZZZZZQ发布了新的文献求助10
4秒前
4秒前
小刘完成签到,获得积分10
4秒前
4秒前
ZS发布了新的文献求助10
5秒前
完美萤完成签到,获得积分10
6秒前
liuhll发布了新的文献求助10
6秒前
NexusExplorer的应助被好家伙采纳,获得10
6秒前
6秒前
mengxiang完成签到,获得积分20
6秒前
Ada完成签到 ,获得积分10
6秒前
zgw完成签到,获得积分10
6秒前
风禾尽起发布了新的文献求助10
6秒前
nauj完成签到 ,获得积分10
6秒前
xxxxxx完成签到,获得积分10
7秒前
StrawCc完成签到 ,获得积分10
7秒前
7秒前
经纬完成签到,获得积分10
7秒前
粉蒸肉完成签到,获得积分10
7秒前
留无影完成签到,获得积分10
8秒前
chentong完成签到,获得积分0
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162